Chakra Biotech Sdn Bhd Completes Series B Investment Round
Chakra Biotech Sdn Bhd, a Malaysian based contract research Organization (CRO), has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.
Chakra Biotech CEO Anthony Bishop said, "The Series B investment is a strong sign of the confidence we share with our investors that our full range of service offerings are valuable to our customers, particularly our proprietary chakragati (ckr) mouse model for screening new psychiatric drugs."
The ckr mouse model is a US Patented transgenic model of psychiatric disease.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Ablynx Announces Positive Phase I Results for Subcutaneous Administration of it’s Anti-thrombotic Nanobody (ALX-0681)

A molecular assembly method for cancer therapy and diagnostics
Thermo Fisher Scientific acquires Open Biosystems - Creating unmatched RNAi platform

Simulations show how to make gene therapy more effective

Scientists wage fight against aging bone marrow stem cell niche
Antisoma's AS1411 gains US and EU Orphan Drug Status for acute myeloid leukaemia
